TABLE OF CONTENTS
1 INTRODUCTION 74
1.1 OBJECTIVES OF THE STUDY 74
1.2 MARKET DEFINITION 74
1.3 OVERVIEW OF THE MIDDLE EAST & AFRICA FECAL OCCULT BLOOD TESTS MARKET 74
1.4 CURRENCY AND PRICING 76
1.5 LIMITATIONS 76
1.6 MARKETS COVERED 76
2 MARKET SEGMENTATION 80
2.1 MARKETS COVERED 80
2.2 GEOGRAPHICAL SCOPE 81
2.3 YEARS CONSIDERED FOR THE STUDY 82
2.4 DBMR TRIPOD DATA VALIDATION MODEL 83
2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 86
2.6 MULTIVARIATE MODELLING 87
2.7 PRODUCT TYPE SEGMENT LIFELINE CURVE 87
2.8 MARKET APPLICATION COVERAGE GRID 88
2.9 DBMR MARKET POSITION GRID 89
2.10 VENDOR SHARE ANALYSIS 90
2.11 SECONDARY SOURCES 91
2.12 ASSUMPTIONS 91
3 EXECUTIVE SUMMARY 92
4 PREMIUM INSIGHTS 94
4.1 PESTEL ANALYSIS 95
4.2 PORTER'S 5 FORCES 96
5 INDUSTRY INSIGHTS 97
6 REGULATORY FRAMEWORK 99
6.1 REGULATORY SCENARIO BY U.S. FDA 99
6.2 REGULATORY SCENARIO IN U.S. 99
6.3 REGULATORY SCENARIO IN EUROPE 100
6.4 REGULATORY SCENARIO IN CANADA 100
6.5 REGULATORY SCENARIO IN AUSTRALIA 100
7 MARKET OVERVIEW 101
7.1 DRIVERS 103
7.1.1 RISING CASES OF COLORECTAL CANCER MIDDLE EAST & AFRICALY 103
7.1.2 DEVELOPMENT OF DIRECT-TO-CONSUMER LABORATORY TESTING 103
7.1.3 EASY AVAILABILITY OF FECAL OCCULT IMMUNOLOGICAL TEST DEVICES IN ONLINE STORES 104
7.1.4 INCREASING INCLINATION TOWARDS POINT-OF-CARE DIAGNOSTICS 104
7.2 RESTRAINTS 104
7.2.1 CHANGE IN CONSUMER PREFERENCE TOWARDS COST-EFFECTIVE ALTERNATIVES 104
7.2.2 LOW AWARENESS ABOUT FECAL OCCULT BLOOD TESTS IN UNDEVELOPED COUNTRIES 105
7.3 OPPORTUNITIES 105
7.3.1 INCREASE IN SCREENING PROCEDURES 105
7.3.2 RISING TECHNICAL ADVANCEMENTS 106
7.3.3 STRATEGIC INITIATIVES 106
7.4 CHALLENGES 107
7.4.1 LACK OF SKILLED PROFESSIONALS 107
7.4.2 LOW EFFICIENCY 107
8 MIDDLE EAST & AFRICA FECAL OCCULT BLOOD TESTS MARKET, BY TEST TYPE 108
8.1 OVERVIEW 109
8.2 LATERAL FLOW IMMUNO-FOB TEST KITS 112
8.3 IMMUNO-FOB AGGLUTINATION TEST KITS 112
8.4 IMMUNO-FOB ELISA TEST KITS 113
8.5 GUAIAC FOB STOOL TEST 114
8.5.1 KITS 115
8.5.1.1 GUAIAC SLIDES 115
8.5.1.1.1 25 PACKAGE 115
8.5.1.1.2 20 PACKAGE 115
8.5.1.1.3 OTHERS 115
8.5.1.2 ALPHA GUAIACONIC ACID (GUAIAC) IMPREGNATED PAPER 116
8.5.1.2.1 SENSITIVITY IS 50NG/ML 116
8.5.1.2.1.1 25 PACKAGE 116
8.5.1.2.1.2 20 PACKAGE 116
8.5.1.2.1.3 OTHERS 117
8.5.1.2.2 SENSITIVITY IS 75NG/ML 117
8.5.1.2.2.1 25 PACKAGE 117
8.5.1.2.2.2 20 PACKAGE 117
8.5.1.2.2.3 OTHERS 117
8.5.1.2.3 OTHERS 117
8.5.1.3 OTHERS 118
8.5.2 REAGENTS 118
8.5.2.1 HYDROGEN PEROXIDE 118
8.5.2.2 OTHERS 118
8.6 FLUSHABLE REAGENT PAD OR TISSUE 118
8.7 OTHERS 119
9 MIDDLE EAST & AFRICA FECAL OCCULT BLOOD TESTS MARKET, BY APPLICATION 120
9.1 OVERVIEW 121
9.2 COLORECTAL CANCER SCREENING 124
9.2.1 LATERAL FLOW IMMUNO-FOB TEST KITS 125
9.2.2 IMMUNO-FOB AGGLUTINATION TEST KITS 125
9.2.3 IMMUNO-FOB ELISA TEST KITS 125
9.2.4 GUAIAC FOB STOOL TEST 125
9.2.5 FLUSHABLE REAGENT PAD OR TISSUE 125
9.2.6 OTHERS 125
9.3 CONCERN FOR GASTROINTESTINAL BLEEDING 125
9.3.1 LATERAL FLOW IMMUNO-FOB TEST KITS 126
9.3.2 IMMUNO-FOB AGGLUTINATION TEST KITS 126
9.3.3 IMMUNO-FOB ELISA TEST KITS 126
9.3.4 GUAIAC FOB STOOL TEST 127
9.3.5 FLUSHABLE REAGENT PAD OR TISSUE 127
9.3.6 OTHERS 127
9.4 POLYPS 127
9.4.1 LATERAL FLOW IMMUNO-FOB TEST KITS 128
9.4.2 IMMUNO-FOB AGGLUTINATION TEST KITS 128
9.4.3 IMMUNO-FOB ELISA TEST KITS 128
9.4.4 GUAIAC FOB STOOL TEST 128
9.4.5 FLUSHABLE REAGENT PAD OR TISSUE 128
9.4.6 OTHERS 128
9.5 DIVERTICULOSIS 129
9.5.1 LATERAL FLOW IMMUNO-FOB TEST KITS 130
9.5.2 IMMUNO-FOB AGGLUTINATION TEST KITS 130
9.5.3 IMMUNO-FOB ELISA TEST KITS 130
9.5.4 GUAIAC FOB STOOL TEST 130
9.5.5 FLUSHABLE REAGENT PAD OR TISSUE 130
9.5.6 OTHERS 130
9.6 ULCERS 130
9.6.1 LATERAL FLOW IMMUNO-FOB TEST KITS 131
9.6.2 IMMUNO-FOB AGGLUTINATION TEST KITS 131
9.6.3 IMMUNO-FOB ELISA TEST KITS 131
9.6.4 GUAIAC FOB STOOL TEST 132
9.6.5 FLUSHABLE REAGENT PAD OR TISSUE 132
9.6.6 OTHERS 132
9.7 HAEMORRHOIDS 132
9.7.1 LATERAL FLOW IMMUNO-FOB TEST KITS 133
9.7.2 IMMUNO-FOB AGGLUTINATION TEST KITS 133
9.7.3 IMMUNO-FOB ELISA TEST KITS 133
9.7.4 GUAIAC FOB STOOL TEST 133
9.7.5 FLUSHABLE REAGENT PAD OR TISSUE 133
9.7.6 OTHERS 133
9.8 COLITIS 134
9.8.1 LATERAL FLOW IMMUNO-FOB TEST KITS 135
9.8.2 IMMUNO-FOB AGGLUTINATION TEST KITS 135
9.8.3 IMMUNO-FOB ELISA TEST KITS 135
9.8.4 GUAIAC FOB STOOL TEST 135
9.8.5 FLUSHABLE REAGENT PAD OR TISSUE 135
9.8.6 OTHERS 135
9.9 ANEMIA 135
9.9.1 LATERAL FLOW IMMUNO-FOB TEST KITS 136
9.9.2 IMMUNO-FOB AGGLUTINATION TEST KITS 136
9.9.3 IMMUNO-FOB ELISA TEST KITS 136
9.9.4 GUAIAC FOB STOOL TEST 137
9.9.5 FLUSHABLE REAGENT PAD OR TISSUE 137
9.9.6 OTHERS 137
9.10 OTHERS 137
10 MIDDLE EAST & AFRICA FECAL OCCULT BLOOD TESTS MARKET, BY END USER 138
10.1 OVERVIEW 139
10.2 DIAGNOSTIC LABORATORIES 142
10.3 HOSPITALS 142
10.4 SPECIALITY CLINICS 143
10.5 OTHERS 144
11 MIDDLE EAST & AFRICA FECAL OCCULT BLOOD TESTS MARKET, BY DISTRIBUTION CHANNEL 145
11.1 OVERVIEW 146
11.2 DIRECT TENDER 149
11.3 RETAIL SALE 149
11.4 E-COMMERCE 150
11.5 OTHERS 151
12 MIDDLE EAST & AFRICA FECAL OCCULT BLOOD TESTS MARKET, BY REGION 152
12.1 MIDDLE EAST AND AFRICA 153
12.1.1 SOUTH AFRICA 168
12.1.2 SAUDI ARABIA 178
12.1.3 U.A.E. 188
12.1.4 EGYPT 198
12.1.5 ISRAEL 208
12.1.6 REST OF MIDDLE EAST AND AFRICA 218
13 MIDDLE EAST & AFRICA FECAL OCCULT BLOOD TESTS MARKET: COMPANY LANDSCAPE 219
13.1 COMPANY SHARE ANALYSIS: MIDDLE EAST & AFRICA 219
14 SWOT ANALYSIS 220
15 COMPANY PROFILE 221
15.1 QUIDEL CORPORATION 221
15.1.1 COMPANY SNAPSHOT 221
15.1.2 REVENUE ANALYSIS 221
15.1.3 COMPANY SHARE ANALYSIS 222
15.1.4 PRODUCT PORTFOLIO 222
15.1.5 RECENT DEVELOPMENT 222
15.2 WONDFO. 223
15.2.1 COMPANY SNAPSHOT 223
15.2.2 COMPANY SHARE ANALYSIS 223
15.2.3 PRODUCT PORTFOLIO 224
15.2.4 RECENT DEVELOPMENT 224
15.3 SIEMENS HEALTHCARE GMBH 225
15.3.1 COMPANY SNAPSHOT 225
15.3.2 REVENUE ANALYSIS 225
15.3.3 COMPANY SHARE ANALYSIS 226
15.3.4 RODUCT PORTFOLIO 226
15.3.5 RECENT DEVELOPMENT 226
15.4 EIKEN CHEMICAL CO., LTD. 227
15.4.1 COMPANY SNAPSHOT 227
15.4.2 REVENUE ANALYSIS 227
15.4.3 COMPANY SHARE ANALYSIS 228
15.4.4 PRODUCT PORTFOLIO 228
15.4.5 RECENT DEVELOPMENT 228
15.5 BIOHIT OYJ 229
15.5.1 COMPANY SNAPSHOT 229
15.5.2 REVENUE ANALYSIS 229
15.5.3 COMPANY SHARE ANALYSIS 230
15.5.4 PRODUCT PORTFOLIO 230
15.5.5 RECENT DEVELOPMENT 230
15.6 ACCUBIOTECH CO LTD 231
15.6.1 COMPANY SNAPSHOT 231
15.6.2 PRODUCT PORTFOLIO 231
15.6.3 RECENT DEVELOPMENT 231
15.7 ACCUQUIK TEST KITS 232
15.7.1 COMPANY SNAPSHOT 232
15.7.2 PRODUCT PORTFOLIO 232
15.7.3 RECENT DEVELOPMENT 232
15.8 AIDIAN 233
15.8.1 COMPANY PROFILE 233
15.8.2 PRODUCT PORTFOLIO 233
15.8.3 RECENT DEVELOPMENT 233
15.9 ALFA SCIENTIFIC DESIGNS, INC. 234
15.9.1 COMPANY SNAPSHOT 234
15.9.2 PRODUCT PORTFOLIO 234
15.9.3 RECENT DEVELOPMENT 234
15.10 APACOR LIMITED 235
15.10.1 COMPANY SNAPSHOT 235
15.10.2 PRODUCT PORTFOLIO 235
15.10.3 RECENT DEVELOPMENT 235
15.11 BIOPANDA REAGENTS LTD 236
15.11.1 COMPANY SNAPSHOT 236
15.11.2 PRODUCT PORTFOLIO 236
15.11.3 RECENT DEVELOPMENT 236
15.12 BODITECH MED INC. 237
15.12.1 COMPANY SNAPSHOT 237
15.12.2 PRODUCT PORTFOLIO 237
15.12.3 RECENT DEVELOPMENT 237
15.13 CENOGENICS CORPORATION 238
15.13.1 COMPANY SNAPSHOT 238
15.13.2 PRODUCT PORTFOLIO 238
15.13.3 RECENT DEVELOPMENT 238
15.14 CERTEST BIOTEC. 239
15.14.1 COMPANY SNAPSHOT 239
15.14.2 PRODUCT PORTFOLIO 239
15.14.3 RECENT DEVELOPMENT 239
15.15 CTK BIOTECH, INC. 240
15.15.1 COMPANY SNAPSHOT 240
15.15.2 PRODUCT PORTFOLIO 240
15.15.3 RECENT DEVELOPMENT 240
15.16 EDP BIOTECH 241
15.16.1 COMPANY SNAPSHOT 241
15.16.2 PRODUCT PORTFOLIO 241
15.16.3 1.16.3 RECENT DEVELOPMENT 241
15.17 EPITOPE DIAGNOSTICS, INC. 242
15.17.1 COMPANY SNAPSHOT 242
15.17.2 PRODUCT PORTFOLIO 242
15.17.3 RECENT DEVELOPMENT 242
15.18 EUROLYSER DIAGNOSTICA GMBH 243
15.18.1 COMPANY SNAPSHOT 243
15.18.2 PRODUCT PORTFOLIO 243
15.18.3 RECENT DEVELOPMENT 243
15.19 FIRSTEP 244
15.19.1 COMPANY SNAPSHOT 244
15.19.2 PRODUCT PORTFOLIO 244
15.19.3 RECENT DEVELOPMENT 244
15.20 HANGZHOU CLONGENE BIOTECH CO., LTD 245
15.20.1 COMPANY SNAPSHOT 245
15.20.2 PRODUCT PORTFOLIO 245
15.20.3 RECENT DEVELOPMENT 245

Menu 2

Sed ut perspiciatis unde omnis iste natus error sit voluptatem accusantium doloremque laudantium, totam rem aperiam.